KHP Ventures is a London-based investment firm established in 2021 that specializes in healthcare innovation. The firm focuses on venture capital investments across various stages, including pre-seed, seed, and series A funding. KHP Ventures targets three key sub-sectors within the healthcare industry: digital health, MedTech, and enterprise software. Its mission is to support innovative ideas that enhance healthcare delivery and technology.
52 North Health is focused on enhancing healthcare for cancer patients, specifically those undergoing chemotherapy, by providing a portable and easy-to-use medical device. This device employs artificial intelligence to assess the risk of neutropenic sepsis, a serious and potentially fatal side effect of chemotherapy. Through a finger prick blood test and a corresponding digital platform, the device measures a patient's neutrophil count and C-reactive protein (CRP) levels at home. This functionality allows for timely identification of patients at risk of sepsis, thereby improving their safety and quality of life. By facilitating rapid management of their condition, 52 North Health offers a reliable and cost-effective solution for cancer patients.
PocDoc
Seed Round in 2024
PocDoc is a digital health platform focused on the monitoring and testing of cardiovascular, metabolic, and renal diseases. The company has developed an innovative solution that combines a smartphone application with a physical test chip, allowing users to conduct a health assessment using just a single drop of blood. This technology measures several key biomarkers to clinical grade, providing real-time analysis of lifestyle diseases. By enabling individuals to gain control over their physical health, PocDoc facilitates the identification of health issues and supports follow-on care pathways.
iFast Diagnostics
Seed Round in 2024
iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.
deepc
Series A in 2024
deepc GmbH, based in Munich, Germany, specializes in developing AI software for medical imaging, particularly in radiology, to minimize diagnostic errors. The company offers a disease-agnostic AI solution that analyzes medical imaging data in real-time, identifying healthy and non-healthy cases to enhance diagnostic accuracy. Its web-based AI software framework, referred to as the Diagnostics OS, facilitates the integration of various medical diagnostic AI tools into clinical workflows, improving efficiency and cost-effectiveness. By serving as a central hub for artificial intelligence applications in radiology, deepc aims to support healthcare professionals in achieving faster, more accurate diagnoses, ultimately leading to better patient outcomes. The company has received recognition for its innovative contributions, including awards from the Federal Ministry for Economic Affairs and Energy.
ACORAI
Seed Round in 2024
Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.
Albus Health
Venture Round in 2024
Albus Health, a startup emerging from the University of Oxford, has created an intelligent nocturnal monitoring platform designed for personalized home use. This system facilitates passive, contactless, and objective monitoring of various symptoms and environmental metrics, making it particularly useful for assessing nocturnal conditions. The platform has been successfully commercialized and is currently employed by leading pharmaceutical companies to monitor nocturnal symptoms during clinical trials. Additionally, it has the capability to predict respiratory emergencies, thus enhancing patient safety and outcomes.
Machine Medicine
Venture Round in 2024
Machine Medicine Technologies Ltd, established in 2017 and based in London, UK, specializes in developing artificial intelligence-driven solutions for healthcare. The company's core product, KELVIN-PD, employs computer vision and pose estimation to objectively measure and analyze movement in patients, particularly those with Parkinson's disease. This platform delivers precise metrics, such as tremor and bradykinesia, from simple video clips, enabling secure, device-agnostic, and affordable patient data management.
Phare Health
Seed Round in 2023
Phare Health operates an AI-driven platform that streamlines healthcare administration. It converts unstructured clinical notes into structured data, empowering hospitals to manage resources effectively, recover costs accurately, and ensure proper reimbursement.
Hypervision Surgical
Seed Round in 2023
Hypervision Surgical focuses on enhancing surgical precision, safety, and efficiency through its innovative imaging technology. The company develops an advanced non-contact and non-invasive optical imaging system that employs hyperspectral imaging to analyze tissues during surgery. By splitting light into multiple spectral bands, the system provides real-time, data-driven tissue characterization, allowing clinicians to visualize and assess tissue without the need for contrast agents. This technology aims to improve surgical outcomes while minimizing risks to patients, positioning Hypervision Surgical at the forefront of AI-powered surgical assistance.
Apian
Seed Round in 2023
Apian specializes in integrating drones into the healthcare sector by developing an API and various products that facilitate this connection. The company offers a range of electric drones, including fixed-wing hybrid VTOL models for long-range flights and multi-rotor drones for shorter, more accessible missions. By enhancing medical logistics through drone technology, Apian aims to improve patient health outcomes and support healthcare staff. Their solutions are designed to be simple, scalable, and sustainable, enabling healthcare clients to deliver smarter and more efficient services.
MediShout
Seed Round in 2023
MediShout Ltd. is a London-based company that develops a digital platform aimed at enhancing operational efficiency within healthcare settings such as hospitals, general practices, and care homes. Established in 2013, the platform connects healthcare teams, suppliers, and various systems, facilitating better communication and workflow among staff. By integrating features like two-way conversations, instant feedback, and artificial intelligence, MediShout addresses inefficiencies in hospital environments, helping to streamline processes and predict future challenges. The technology aims to reduce delays in patient care and optimize resource utilization, allowing healthcare professionals to focus more on patient needs and less on administrative burdens.
TympaHealth
Series A in 2023
TympaHealth has developed an innovative ear and hearing health assessment system that allows non-specialists to conduct comprehensive evaluations. The Tympa platform enables clinicians to perform high-definition digital otoscopy, microsuction wax removal, and hearing screenings during a single 30-minute appointment. Additionally, users can securely upload patient images and videos to the cloud, facilitating remote review by ENT specialists worldwide. This service aims to enhance ear and hearing health outcomes by equipping allied healthcare professionals with the tools necessary for effective diagnosis and treatment.
52 North
Seed Round in 2023
52 North Health is focused on enhancing healthcare for cancer patients, specifically those undergoing chemotherapy, by providing a portable and easy-to-use medical device. This device employs artificial intelligence to assess the risk of neutropenic sepsis, a serious and potentially fatal side effect of chemotherapy. Through a finger prick blood test and a corresponding digital platform, the device measures a patient's neutrophil count and C-reactive protein (CRP) levels at home. This functionality allows for timely identification of patients at risk of sepsis, thereby improving their safety and quality of life. By facilitating rapid management of their condition, 52 North Health offers a reliable and cost-effective solution for cancer patients.
Feebris
Venture Round in 2023
Feebris Ltd is a technology company founded in 2017 and based in Saffron Walden, United Kingdom. The company specializes in developing artificial intelligence and machine learning algorithms aimed at the detection of respiratory conditions. Its platform integrates with various point-of-care devices, such as digital stethoscopes and wearables, to facilitate community-based diagnosis and monitoring. By leveraging its AI-driven software, Feebris enables non-clinical users to identify clinical deterioration early, thereby helping to prevent complications and reduce hospitalizations. The team at Feebris combines expertise in biomedical engineering, machine learning, and global health, all driven by a commitment to transforming healthcare into a more equitable, personalized, and patient-centered system.
iFast Diagnostics
Seed Round in 2023
iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.
WeWALK
Venture Round in 2022
WeWALK Limited is a company based in London, United Kingdom, that develops innovative mobility tools for visually impaired individuals. Founded in 2017, WeWALK has created a smart cane equipped with advanced technology, including an ultrasonic sensor that detects obstacles above chest level and vibrates to alert users of nearby objects. This smart cane is enhanced by the WeWalk mobile application, which facilitates outdoor navigation, wayfinding, and public transportation integration. The company aims to empower visually impaired individuals by promoting independence and safety in their daily lives, thereby fostering social inclusion and transforming mobility experiences through the use of artificial intelligence and modern technology.
Acurable
Series A in 2022
Acurable Limited is a MedTech start-up based in London that specializes in the design and commercialization of a wearable sensor-based health care device aimed at diagnosing and managing respiratory conditions in a non-invasive manner. The company's flagship product, AcuPebble, allows for the diagnosis of sleep apnea and the monitoring of various respiratory and cardiac conditions through advanced algorithms that analyze acoustic signals. This technology, which emerged from a decade of research at Imperial College London, provides more accurate readings than existing solutions, significantly reducing the risk of misdiagnosis. AcuPebble is designed for home use, requiring no specialist training, which helps lower healthcare costs. Acurable's mission is to gain a comprehensive understanding of human biosignals to ensure that treatable conditions do not result in preventable deaths.
Apian
Seed Round in 2022
Apian specializes in integrating drones into the healthcare sector by developing an API and various products that facilitate this connection. The company offers a range of electric drones, including fixed-wing hybrid VTOL models for long-range flights and multi-rotor drones for shorter, more accessible missions. By enhancing medical logistics through drone technology, Apian aims to improve patient health outcomes and support healthcare staff. Their solutions are designed to be simple, scalable, and sustainable, enabling healthcare clients to deliver smarter and more efficient services.
Doccla
Series A in 2022
Doccla is a provider of virtual ward services that focuses on shifting patient care from hospitals to home settings. The company partners with care organizations to facilitate early patient discharge and reduce hospital readmissions through remote monitoring using advanced medical devices. By onboarding patients at home with the necessary monitoring equipment, Doccla employs a mobile team of healthcare professionals, including nurses and doctors, to oversee patient care. This approach not only ensures that patients receive timely and effective treatment but also aims to enhance care quality while lowering associated costs. Originally developed as part of a research initiative for the NHS, Doccla's innovative service has been successfully implemented in collaboration with Northampton General Hospital.
Patchwork Health
Series B in 2022
Patchwork Health, founded in 2016 by NHS doctors Anas Nader and Jing Ouyang, is a healthcare workforce platform that addresses temporary staffing challenges within the NHS. The company connects vacant shifts with a marketplace of healthcare professionals, thereby enhancing fill rates for temporary positions. By facilitating direct connections between healthcare organizations and local staff banks, Patchwork Health not only optimizes staffing levels but also improves patient safety and the overall experience for healthcare workers. The platform ultimately aims to ensure that qualified professionals are available when needed, contributing to better patient care and significant cost savings for the NHS.
ACORAI
Seed Round in 2022
Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.